Stem Cell Transplantation

Mycophenolate mofetil effective against GvHD but carries high infection risk

Published in Blood Weekly, October 31st, 2002

by Michael Greer, senior medical writer - Mycophenolate mofetil (MMF) can control graft-versus-host reactions to stem cell grafts but carries substantial risks of its own, researchers in France report.

Marion Baudard and colleagues at Hotel-Dieu University Hospital in Nantes evaluated the benefits and drawbacks of MMF therapy to treat posttransplant graft-versus-host disease (GvHD).

This immunosuppressant is effective against GvHD but significantly increases the risk of infectious morbidity, Baudard and coauthors found.

The researchers reviewed data from 21 patients who developed acute or chronic GvHD after stem cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry